605
Views
3
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Hepatocellular carcinoma – Pathological complete response to oral capecitabine, megestrol and thalidomide

, &
Pages 95-97 | Received 20 Jun 2005, Published online: 08 Jul 2009

References

  • Seow, A, Koh, WP, Chia, KS, Shi, LM, Lee, HP, Shanmugaratnam, K. Trends in cancer incidence in Singapore 1968–2002, Singapore Cancer Registry Report No.6.
  • Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallblader carcinoma. Cancer 2004; 101: 578–86
  • Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low–dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 242–9
  • Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 881–5
  • Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990; 65: 2641–3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.